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Abstract
 
Complement has been implicated in liver repair after toxic injury. Here, we demonstrate that
complement components are essential for liver regeneration, and mediate their effect by inter-
acting with key signaling networks that promote hepatocyte proliferation. C3- or C5-deficient
mice exhibited high mortality, parenchymal damage, and impaired liver regeneration after partial
hepatectomy. Mice with dual C3 and C5 deficiency had a more exacerbated phenotype that
was reversed by combined C3a and C5a reconstitution. Interception of C5a receptor signaling
resulted in suppression of IL-6/TNF
 
 
 
 induction and lack of C3 and C5a receptor stimulation
attenuated nuclear factor–
 
 
 
B/STAT-3 activation after hepatectomy. These data indicate that
C3a and C5a, two potent inflammatory mediators of the innate immune response, contribute
essentially to the early priming stages of hepatocyte regeneration.
Key words: complement • anaphylatoxins • NF-
 
 
 
B • STAT-3 • IL-6
 
Introduction
 
Growing evidence suggests that complement proteins not
only serve as mediators of innate immune defense against
foreign pathogens but can also modulate diverse develop-
mental processes, such as cell survival, growth, and differ-
entiation in various tissues (1, 2). In this respect, complement
has recently been implicated as a mediator of lens and limb
regeneration in lower vertebrates (3, 4).
In mammals, the liver constitutes a well-established para-
digm of tissue regeneration, which can occur after toxic
exposure, viral injury, or surgical resection. Terminally dif-
ferentiated liver cells respond to these perturbations by
shedding their quiescent phenotype and by undergoing
several cycles of cell division to regenerate lost parenchymal
liver mass (5). Liver regeneration is a well-orchestrated and
tightly regulated process that proceeds through distinct
stages, including priming of hepatocytes, cell cycle pro-
gression, proliferation, and cessation of regeneration (6).
The signaling pathways underlying the early priming
phase of liver regeneration are thought to be triggered by
the synergistic effect of a wide array of stimuli, including
cytokines (7), prostaglandins (8), hormones (9), reactive oxy-
gen species (10), and lipopolysaccharides (11, 12) released into
the portal circulation. Within this signaling network, IL-6
and TNF
 
 
 
 (7), as well as their downstream transcription
factors STAT-3 and nuclear factor (NF)–
 
 
 
B (13), have
been identified as crucial regulators of the regenerative process.
However, to this date, the potential interaction of these
cytokine-driven pathways in the liver with cellular or humoral
components of the innate immune response, as well as the
molecular mechanisms by which such a “crosstalk” might
affect the early stages of hepatocyte regeneration, have not
been addressed.
In support of this concept, recent works have revealed
novel modulatory roles of complement in the hepatic mi-
croenvironment. C5a has been shown to costimulate pros-
taglandin and cytokine secretion from Kupffer cells, and to
modulate glucose release and acute-phase gene expression
in hepatocytes, in a C5a receptor (C5aR)–dependent fashion
(14). Likewise, C3a can mediate metabolic functions in
cultured liver macrophages (15) and ex vivo–perfused livers
(16). These findings, together with our earlier observation
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that C5
 
 
 
/
 
 
 
 mice are more susceptible to liver toxic damage
(17), formed the conceptual framework of our hypothesis
that complement is a critical mediator of liver regeneration.
To define the role of complement in the regenerative pro-
cess and dissect the molecular interactions of various compo-
nents with the early signaling networks that promote
hepatocyte proliferation, we performed partial hepatectomy
(PHx) studies using mice deficient in C3 and C5, two critical
components of the complement cascade. Using C3a and C5a
in reconstitution studies, we have established that both ana-
phylatoxins are required for normal liver regeneration and
that their stimulatory effect is mediated in an independent
and cooperative fashion. Intercepting specific receptor-medi-
ated pathways, we have identified a novel mechanistic asso-
ciation between the complement and cytokine networks in
promoting hepatocyte priming and proliferation.
 
Materials and Methods
 
Animals. 
 
14–18-wk-old specific pathogen-free mice were
used in all experiments. C57BL6-J, B10D2oSn-J (C5
 
 
 
/
 
 
 
), and
B10D2nSn-J (C5
 
 
 
/
 
 
 
) mice were purchased from the Jackson Labo-
ratory. C3
 
 
 
/
 
 
 
, C3
 
 
 
/
 
 
 
 (both C57BL6), C3
 
 
 
/
 
 
 
C5
 
 
 
/
 
 
 
, and C3
 
 
 
/
 
 
 
C5
 
 
 
/
 
 
 
 mice were bred in-house. The C3
 
 
 
/
 
 
 
C5
 
 
 
/
 
 
 
 and C3
 
 
 
/
 
 
 
C5
 
 
 
/
 
 
 
 mice were newly generated by crossbreeding the corre-
sponding C3 and C5 strains. Bacterial colonization or infections that
could interfere with the regenerative phenotype of the animals in-
cluded into the work were ruled out by histological analysis. Lungs,
livers (including the resected part of the liver at the time of PHx),
kidneys, spleens, duodenums, and hearts were investigated for signs
of inflammatory processes. None of these tissue samples showed
signs of inflammation or bacterial colonization. The presence of
helicobacter species in the livers of mice from our colony was ex-
cluded by randomly analyzing the livers of three C3
 
 
 
/
 
 
 
C5
 
 
 
/
 
 
 
 mice
by PCR, which gave negative results. The PCR studies were per-
formed by the Missouri University Research Animal Diagnostic
Laboratory (Columbia, MO). All animal studies were conducted in
compliance with the guidelines of the University of Pennsylvania,
according to an animal protocol approved by the University of
Pennsylvania Institutional Animal Care and Use Committee.
 
Partial Hepatectomy. 
 
Approximately 70% PHx was performed
according to the method of Higgins et al. (18). The median and
left lateral lobes were removed without injuring the remaining
liver tissue. In case of severe morbidity (lethargy, trembling, an-
orexia, or body temperature loss), animals were killed and re-
garded as nonsurvivors. 
To assess the proliferative response of hepatocytes, mice re-
ceived 50 mg/kg body weight of 5-bromo-2
 
 
 
-deoxyuridine
(BrdU; Sigma-Aldrich) i.p. 1 h before tissue harvests. C5aR
blockade was achieved by i.p. injection of the cyclic hexapeptide
AcF[OpdChaWR] 20 min before surgery (1 mg/kg in PBS)
(control: peptide IAVVQDWGHHRAT-CONH
 
2
 
, 1 mg/kg in
PBS). Animals were perfused with a 10% buffered formaldehyde
solution, in which tissues were also placed for paraffin embedding
and sectioning. Alternatively, the perfusion was done with PBS
and protein extraction.
 
Liver Morphology. 
 
Liver histology was assessed by light mi-
croscopy (model BX 60; Olympus) of hematoxylin- and eosin-
stained 5-
 
 
 
m sections in a blinded fashion. The extent of necrosis
was semi-quantitatively estimated by assigning a severity score
(absent, 0; mild, 1; moderate, 2; pronounced, 3; and severe, 4).
This score was used to compare the liver damage after PHx be-
tween different strains. To compare parenchymal liver necrosis
between C3
 
 
 
/
 
 
 
C5
 
 
 
/
 
 
 
, C3
 
 
 
/
 
 
 
C5
 
 
 
/
 
 
 
, and anaphylatoxin-recon-
stituted C3
 
 
 
/
 
 
 
C5
 
 
 
/
 
 
 
 mice (see Fig. 3), the quantification was
performed blinded with the Scion Image Software, version 4.0.2.
(National Institutes of Health) using histological slides.
 
Serum Biochemistry. 
 
Serum samples from all mice were col-
lected for measurement of alanine aminotransferase, aspartate
aminotransferase, alkaline phosphatase, albumin, and total biliru-
bin and were stored at 
 
 
 
20
 
 
 
C until analysis. All enzymatic assays
were performed by Anilytics.
 
BrdU Immunohistochemistry. 
 
Nuclear staining of hepatocytes
for BrdU uptake was performed with modifications as described
previously (17). The total number of BrdU-labeled hepatocytes
was determined by counting positively stained nuclei in 10 high-
power fields (
 
 
 
400). Constantly proliferating intestinal crypt epi-
thelium from small intestine served as a positive control for BrdU
incorporation and staining.
 
RNA Isolation and Detection of IL-6 and TNF
 
 
 
 mRNA by Semi-
quantitative RT-PCR. 
 
Total liver RNA was prepared, and cy-
tokine RT-PCRs were performed as described previously (19).
Primers used were as follows: IL-6, 5
 
 
 
-primer, 5
 
 
 
-TTCCATC-
CAGTTGCCTTCTT-3
 
 
 
, 3
 
 
 
-primer, 5
 
 
 
-CAGAATTGCCAT-
TGCACAAC-3
 
 
 
 (size of PCR product, 198 bp); TNF
 
 
 
, 5
 
 
 
-
primer, 5
 
 
 
-GGCAGGTCTACTTTGGAGTCATTGC-3
 
 
 
, 3
 
 
 
-
primer, 5
 
 
 
-ACATTCGAGGCTCCAGTGAATTCGG-3
 
 
 
 (size
of PCR product, 307 bp); and 
 
 
 
-actin, 5
 
 
 
-primer, 5
 
 
 
-AGGGT-
GTGATGGTGGGAATGG-3
 
 
 
, 3
 
 
 
-primer, 5
 
 
 
-AGCCAGAG-
CAGTAATCTCCTTCTGC-3
 
 
 
 (size of PCR product, 841 bp).
 
Electrophoretic Mobility Shift Assays and Antibody Supershift As-
says. 
 
Liver nuclear extracts were prepared and electrophoretic
mobility shift assays reactions were performed as described previ-
ously (20, 21). For NF-
 
 
 
B binding, the consensus sequence
5
 
 
 
-AGTTGAGGGGACTTTCCCAGGC-3
 
 
 
 site (Promega) was
used, whereas STAT-3 binding was detected using a gel-purified
oligonucleotide from the sis-inducible factor binding element
in the c-fos promoter (5
 
 
 
-GATCCTCCAGCATTTCCCG-
TAAATCCTCCAG-3
 
 
 
). Rabbit reticulocyte lysate with pre-
identified NF-
 
 
 
B was used to recognize the NF-
 
 
 
B subunit p65
in all assays. Loading control was achieved by detecting E2
binding (5
 
 
 
-GGTTCCAGACCGCGATTGGTGGCTGGA-3
 
 
 
,
a gift from J.I. Leu, University of Pennsylvania, Philadelphia, PA;
reference 22). For supershift experiments, 2 
 
 
 
g/ml polyclonal
rabbit antibodies were used against the p65 subunit on NF-
 
 
 
B
(Cat. No. sc109x) and against STAT-3 (Cat. No. sc482x; both
from Santa Cruz Biotechnology, Inc.).
 
Complement Reagents. 
 
C3 was purified from human plasma
according to a protocol described previously (23). It was applied by
a single i.p. injection 20 min before PHx at a dose of 3 mg/mouse.
C3a was synthesized chemically according to a protocol described
previously (24) with a modification of the cyclization procedure
(25, 26). A 6-His-
 
 
 
–tagged murine C5a was expressed in 
 
Esche-
richia coli
 
 and purified using nickel chelating affinity chromatogra-
phy (27). Three successive doses of the anaphylatoxins, synthetic
mouse C3a, and expressed C5a were also given by i.p. injection at
a dose of 15 
 
 
 
g/mouse/injection (one before and two after PHx,
6-h interval). The C5aR antagonist used in this work is a cyclic
hexapeptide AcF[OpdChaWR] that was synthetically designed
from the COOH terminus of C5a (27). This antagonist has been
shown to specifically block C5a-mediated effects in various rodent
disease models (28). Peptide synthesis and cyclization were per-
formed as described previously (27). The peptide was purified using
preparative reverse phase HPLC. The identity and purity of bothT
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anaphylatoxins was confirmed by mass spectrometry (Maldi-Tof,
Tofspec 2E; Micromass). All reagents injected into mice were ana-
lyzed for their LPS content using a limulus assay (Pyrochrome) and
in all of them it was found to be below 1.5 ng/mg of protein.
 
Statistical Analysis. 
 
Data are expressed as mean 
 
 
 
 SE. The
Mann-Whitney test or the Chi-Square test was used for the de-
termination of significance.
 
Results
 
Liver Damage and Impaired Regeneration in C3
 
 
 
/
 
 
 
 Mice after
PHx.
 
The three pathways of complement activation
(classical, alternative, and lectin) converge at the central
complement component C3. Therefore, C3 deficiency
not only eliminates C3 activation and cleavage into active
C3 fragments but it also largely prevents the downstream
activation of C5 and the release of C5-derived activated
fragments (29).
This central role of C3 was the basis to study the regen-
erative phenotype of the corresponding deficient mice
(C3
 
 
 
/
 
 
 
). In contrast to their wild-type littermates, C3
 
 
 
/
 
 
 
mice displayed an abnormal regenerative response with a
markedly compromised clinical postoperative course. The
clinical deterioration of the C3
 
 
 
/
 
 
 
 mice became evident
between 15 and 24 h after PHx and resulted in a high mor-
Figure 1. Histological and
immunohistochemical findings
in C3   , C5   , C3   C5   ,
and C5   -treated mice and
their controls (Hematoxylin and
eosin stainings, magnification
200). (a) The liver section of a
control animal 44 h after PHx
(representative for all control
strains used). A vigorous regen-
erative response with numerous
mitotic figures ( ) and multi-
nucleated hepatocytes (→) can
be seen. C3 /  (b), C5 /  (c),
and C5aRa-treated animals (d)
44 h after PHx display areas of
parenchymal damage ( ).
Hepatocytes adjacent to necrotic
areas display ballooning degen-
eration (↑). (e–h) Representative
areas from sections of C3 / C5 / 
livers 44 h after PHx without
reconstitution (e), or with recon-
stitution using C3a (f), C5a (g),
or C3a and C5a (h). Severely
injured C3 / C5 /  livers (e)
are partially protected from this
damage after PHx when they are
reconstituted with one of the
two anaphylatoxins (f and g).
When the combination of both
is applied, parenchymal damage
is completely prevented and the
regenerative capacity recovers
(h; mitotic figures,  ).T
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tality of 40% (21:52 mice) as compared with 15% (3:20) for
their wild-type littermates (P   0.05). This clinical impair-
ment was associated with disruption of the lobular architec-
ture of the liver and the presence of randomly distributed
necrotic areas throughout the parenchyma. Ballooning de-
generation was evident in the cytoplasm of hepatocytes ad-
jacent to the necrotic areas (Fig. 1 b). This prominent pres-
ence of necrosis and hepatocyte degeneration in C3 / 
mice correlated with lower BrdU incorporation at 44 h af-
ter hepatectomy and with reduced liver weight recovery in
the surviving C3 /  mice (Fig. 2, a and c).
Biochemical analysis of alanine aminotransferase, aspar-
tate aminotransferase, alkaline phosphatase, and total biliru-
bin serum levels at 44 h after PHx in C3 /  mice revealed
higher aminotransferase values in the C3 /  mice as com-
pared with their controls. These elevated levels of hepatic
enzymes confirmed the observation of a higher incidence
of liver failure and a more pronounced level of liver dam-
age in the C3 /  cohort (unpublished data).
Complement Component C5 Is Required for Normal Liver
Regeneration. C5, the initial component participating in
the assembly of the membrane attack complex, is activated
through cleavage by the classical or alternative pathway C5
convertase, a protein complex containing activated C3
molecules (C3b). Complement activation occurring during
liver regeneration would lead to cleavage and activation of
native C5. Having shown that C3 was required for a nor-
mal regenerative response, we investigated whether C5,
the downstream activation target of C3, might be essential
for liver regeneration too.
Similar to C3 /  mice, C5 /  animals exhibited an ab-
normal regenerative response and increased mortality after
hepatectomy as follows: 23% (9:30) for C5 /  mice as
compared with 4% (1:23) for C5 /  mice (P    0.05).
However, the livers of the surviving C5 /  mice showed
less parenchymal damage than those of C3 /  mice (Fig. 1
c), and the rate of BrdU incorporation into C5 /  hepato-
cytes over time revealed a delayed rather than severely di-
minished DNA synthetic response after PHx when com-
pared with that of wild-type littermates (Fig. 2 d). It should
be noted that this delayed proliferative response of C5 / 
livers had a significant impact on the recovery of liver
weight (Fig. 2 e). As in the case of C3 /  mice, analysis of
aminotransferase and total bilirubin serum levels in C5 / 
Figure 2. Defective hepatocyte S-phase entry after PHx in C3- and C5-deficient mice or after C5aR blockade. Graphs in a, b, d, and f depict numbers
of BrdU-labeled hepatocytes (total number of labeled hepatocytes in 10 high-power fields at various times after PHx). (a) BrdU incorporation levels in
C3 /  (n   9) mice over time are clearly reduced and show a significant difference compared with control (n   8) at 44 h after PHx (P   0.05). (b) Recon-
stitution with either human C3 (n   3) or C3a (n   3) is capable of restoring BrdU incorporation to nearly wild-type levels at 44 h after PHx. (c) The
low number of BrdU-positive nuclei in C3 /  mice is paralleled by a delayed gain in liver weight, as measured by the percentage of original liver weight
before PHx at harvest time. (d) Numbers of BrdU-labeled hepatocytes in C5 /  and C5 /  mice at various times after PHx reveal a delayed peak of
BrdU incorporation. (e) This delay was associated with slower liver weight recovery after PHx. (f) The number of BrdU-positive nuclei is significantly
reduced at 44 h after PHx after C5aRa treatment (P   0.01; BrdU incorporation levels in C5aRa-treated mice [n   10], white bar; BrdU uptake in control
peptide-treated mice [n   3], lightly shaded bar). The same pattern is observed for animals after anti-C5 antibody treatment (n   3, black bar) when
compared with control IgG treatment (n   3, darkly shaded bar; P   0.05).T
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mice at 44 h after PHx confirmed the higher incidence of
liver failure and more pronounced liver damage in this
group (unpublished data).
To further substantiate our finding that C5 is required
for normal liver regeneration, we also assessed the regener-
ative response of wild-type mice treated with a monoclonal
antibody (BB5.1) that inhibits the cleavage of C5 to C5b
and C5a (30). Mice treated with a single preoperative dose
of this anti-C5 antibody showed impaired liver regenera-
tion and diminished BrdU incorporation into hepatocytes
at 44 h after PHx (Fig. 2 f). This finding indicates that C5
activation contributes to the regulation of liver regenera-
tion after PHx.
Combined C3/C5 Deficiency Induces a More Severe Regener-
ative Defect than Single C3 or C5 Deficiency after PHx.
Given that the absence of both C3 and C5 caused defec-
tive regeneration after PHx, it was important to establish
whether C3 merely serves as an intermediate activator of
C5 or whether both components mediate distinct func-
tions; this was explored, for example, by activating differ-
ent pathways via their anaphylatoxins C3a and C5a and
their downstream receptor-mediated interactions. To
evaluate both the independent and combined effects of C3
and C5 and their anaphylatoxins to liver regeneration, we
crossbred both deficient strains and generated a C3/C5
double-deficient strain. These C3 / C5 /  mice provided
an animal model for delineating the independent effect of
isolated components (C3, C5) and also a platform for per-
forming reconstitution experiments with each of their re-
spective anaphylatoxins. Furthermore, choosing to assess
the regenerative response of the double-deficient mice al-
leviated our concern that complement-independent local
activation of C3 or C5 (31) would result in cross-interfer-
ence or compensatory effects in the single-deficient strains.
C3 / C5 /  mice showed no histological sign of liver re-
generation (mitotic figures, cellular hypertrophy) at 44 h
after hepatectomy. Parenchymal necrosis and hepatocyte
degeneration in C3 / C5 /  livers were more pro-
nounced (Fig. 1 e) as well as higher levels of aminotrans-
ferases (not depicted) than in the single-deficient strains.
Similarly, BrdU incorporation into hepatocytes was ex-
tremely low in C3 / C5 /  livers (Fig. 3 a). No mortality
among the C3 / C5 /  animals was observed within the
first 44 h of the observation period. However, all C3 / 
C5 /  displayed clinical signs of liver failure with re-
duced physical activity and dark yellow urine, which pre-
dicted that survival would have been compromised if these
mice had been allowed to stay beyond the 44 h time point.
Figure 3. S-phase entry by hepatocytes after PHx is
abrogated by combined C3 and C5 deficiency and
reversed by anaphylatoxin reconstitution. (a) BrdU in-
corporation into nuclei of hepatocytes from C3 / C5 / 
mice is minimal after PHx (n   16, white bar). Recon-
stitution with C5a (n   7) or C3a (n   4) alone (diag-
onally striped bar) or with the combination of C3a and
C5a (n   5; shaded bar) reverses the proliferative response
partially, as measured by the number of BrdU-positive
nuclei. The reconstitution does not reach the proliferative
response of C3 / C5 /  (n   3, dotted bar) mice.
(b) The same pattern can be detected for liver damage
at 44 h after PHx. The percentage of parenchymal liver
necrosis (quantified with “Scion Image” software;
Materials and Methods) is highest in C3 / C5 /  livers
without reconstitution (white bar). Single reconstitu-
tion with either anaphylatoxin reduces the extent of
necrosis slightly (diagonally striped bar). Simultaneous
reconstitution with C3a and C5a (black bar) reveals a
significant additive protective effect in terms of the
extent of necrosis (P   0.01). (c) The serum levels of
the aspartate amino transferase (I.U./ml) mirror and
confirm the amount of parenchymal damage measured
by histology (b). Combined C3a and C5a reconstitution
(black bar) significantly decreases serum transaminase
levels when compared with untreated C3 / C5 / 
animals (white bar).T
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In a group of eight C3 / C5 /  mice that were allowed
to survive until 96 h after PHx, three animals died (un-
published data). Five animals showed recovery of their
liver function accompanied by increasing liver weight 96 h
after PHx and after transient clinical signs of liver dysfunc-
tion (icteric urine, low physical activity). These observa-
tions suggest that C3 / C5 /  mice eventually regenerate
once they have survived a period of liver dysfunction that
is probably due to their delayed onset of regeneration. To-
gether, these results strongly indicate that C3 and C5 act
cooperatively in inducing hepatocyte proliferation and
that they also have distinct functions required to initiate
the regenerative response.
C3a and C5a Exert a Cooperative Effect during Liver Regen-
eration. Reconstitution of C3 /  mice with human C3 or
murine C3a reversed liver damage and significantly re-
stored hepatocyte proliferation (Fig. 2 b) In light of this
finding, we subsequently reconstituted C3 / C5 /  mice
with synthetic C3a and recombinant C5a to assess whether
these cleavage products of C3 and C5, respectively, medi-
ate independent effects during liver regeneration.
Single reconstitutions with C3a (Fig. 1 f) or C5a (Fig. 1
g) decreased parenchymal damage and increased hepatocyte
BrdU incorporation (Fig. 3 a). The combined application
of both anaphylatoxins had an additive effect in terms of
protection from liver failure and tissue damage (Fig. 1 h
and Fig. 3 b) as well as in inducing hepatocyte prolifera-
tion. However, the reconstitution with both anaphylatox-
ins was not able to completely restore the proliferative re-
sponse to that of wild-type animals (Fig. 3 a), which may
be due to the rapid inactivation of the injected anaphyla-
toxins by carboxypeptidases (32).
The cooperative effect of C3a and C5a in preventing
liver failure and promoting hepatocyte proliferation was
also reflected by the serum aminotransferase profile of the
C3a/C5a-reconstituted C3 / 5 /  mice at 44 h after PHx
(Fig. 3 c). These results strongly suggest that both C3 and
C5 contribute to normal liver regeneration and that this is
achieved by the concerted action of both anaphylatoxins
C3a and C5a.
C5aR Blockade Disrupts Liver Regeneration after PHx.
To further dissect the mechanism by which complement
anaphylatoxins promote the mitogenic priming of hepato-
cytes after PHx, we focused on the action of C5a and as-
sessed whether C5aR–CD88-mediated interactions are in-
volved in the early priming stage of liver regeneration. For
this purpose, mice were treated with a specific C5a recep-
tor antagonist (C5aRa; references 28, 33) before PHx.
This small peptide antagonist of C5aR exhibits highly in-
hibitory properties for C5a-mediated functions and has
been used previously and characterized in several animal
models (28). C5aRa treatment almost completely abro-
gated liver regeneration, with a high mortality of 37% (6:
16), as compared with 0% (0:3 mice) for their peptide-
treated controls (P   0.05) at 44 h after surgery. Hepato-
cyte DNA synthesis was almost completely inhibited (Fig.
2 f), and extensive parenchymal damage was evident at
44 h after PHx (Fig. 1 d). The total number of control an-
imals used in these studies was 12. This number includes
control peptide-treated and nontreated animals because we
found no differences between the two control groups. In
Fig. 2 f, only the results from the control peptide-treated
animals are included. The detrimental effect of C5aR
blockade on liver regeneration indicated that the anaphy-
latoxin C5a exerts its stimulatory effect on hepatocytes via
C5aR-mediated interactions.
Intrahepatic TNF  and IL-6 Release after PHx Requires
C5aR Stimulation. To determine whether the prolifera-
tive effect mediated by C5aR activation involves modula-
tion of cytokine responses in the liver, we investigated the
influence of C5aR blockade on the intrahepatic expression
of TNF  and IL-6 immediately after PHx. Both of these
cytokines are among the earliest priming factors that have
been implicated in liver regeneration after loss of parenchy-
Figure 4. C5aRa blockade decreases TNFa (a)
and IL-6 (b) mRNA synthesis in whole liver mRNA
extracts during the early phase after PHx. (a) Black
bars show the levels of TNF  mRNA synthesis in
livers of C5aRa-treated animals in densitometric arbitrary
units at 0, 3, and 6 h. Gray bars show the corre-
sponding values for control peptide-treated animals.
The quantification was performed on the bases of
relative intensities of the corresponding bands in the
displayed agarose gels. Normalization was done according
to  -actin mRNA intensity in each sample to com-
pensate for loading differences. Control peptide-
treated animals showed a constant decrease in TNF 
mRNA synthesis over time after PHx. In C5aRa-
treated animals, this decrease was more pronounced
than in control livers at 3 and 6 h after PHx. (b)
Black bars show the relative levels of IL-6 mRNA
synthesis in livers of C5aRa-treated animals at 0, 3,
and 6 h. Gray bars show the corresponding values
for control peptide-treated animals (quantification
was performed as described in A). Control peptide-
treated animals show a constant approximate fivefold increase in IL-6 mRNA synthesis over time after PHx. C5aRa treatment causes an abrogation of this
increase in IL-6 mRNA expression. (mRNA samples from three separate experiments were pooled for each time point).T
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mal liver mass (34). Control peptide-treated animals dis-
played a constant induction of TNF  mRNA expression
over time, as determined by semi-quantitative RT-PCR.
In contrast, C5aRa-treated animals showed a decline in
TNF  mRNA levels at 3 and 6 h (Fig. 4 a).
Furthermore, the effect of C5aRa on IL-6 synthesis in
the liver was even more pronounced (Fig. 4 b). Control
peptide-treated animals showed a gradual approximate
twofold increase in IL-6 mRNA level over time. How-
ever, C5aR blockade markedly reduced this induction in
IL-6 mRNA within the first 6 h after PHx. The profiles of
IL-6 and TNF  mRNA expression in other organs (e.g.,
spleen, lung, and kidney) after PHx and C5aRa treatment
were not significantly different from those in control ani-
mals (unpublished data). This finding indicates that the ef-
fect of the C5aRa was highly specific and localized mainly
in the liver and did not affect cytokine release from remote
organs. Together, these results demonstrate that C5a exerts
its effect during liver regeneration by mediating the induc-
tion of proinflammatory cytokines that, in turn, stimulate
hepatocytes to reenter the cell cycle.
C5aR Engagement Recruits NF- B and STAT-3–dependent
Pathways in the Regenerating Liver. The local release of
TNF  and IL-6 and the subsequent stimulation of their re-
ceptors in the liver is coupled to the downstream activation
of the latent transcription factors NF- B and STAT-3 (6).
Both transcription factors have been shown to largely de-
termine the regenerative capacity of hepatocytes in the
early stages after PHx (20). Therefore, the decreased
mRNA levels of IL-6 and TNF  observed in C5aRa-
treated animals after PHx could be associated with de-
creased activation of STAT-3 and NF- B transcription
complexes. To test this hypothesis, the DNA binding activ-
ity of these complexes was assessed in nuclear extracts pre-
pared from C5aRa-treated livers after PHx (Fig. 5, lanes
8–13). NF- B– and STAT-3–binding activity in C5aRa
livers was most prominently reduced at 2 h after surgery,
when compared with control livers (NF- B 60%- and
STAT-3 37%-less activation than in control). This pro-
nounced reduction of transcription factor activation upon
blockade of the C5aR explains in part the severely impaired
regenerative phenotype of the antagonist-treated mice and
identifies a potential molecular pathway by which C5a and
its receptor C5aR modulate the early growth response of
the liver after surgical resection.
Complement Component C3 Is Required for Normal STAT-
3/NF- B Activation during Liver Regeneration. In C3-defi-
cient mice, we observed markedly reduced binding activity
of both transcription factors (NF- B and STAT-3) in liver
nuclear extracts at 1 h after PHx (NF- B 54%- and STAT-3
56%-less activation than in control; Fig. 5, lanes 2–7). Al-
though the pattern of the diminished transcription factor
activation in C3 /  mice was different from that in
C5aRa-treated animals (a prominent difference was ob-
served at 2 h after PHx in C3 /  livers), this finding sug-
gests that both C3 and C5a mediate their stimulatory effect
during liver regeneration by interacting with similar down-
stream signaling effectors.
Discussion
To date, the influence of innate immunity components
on the molecular pathways that regulate liver regeneration
has not been addressed. Here, we report that both comple-
ment components C3 and C5 contribute to liver regenera-
tion after PHx and that this effect is mainly achieved
through the concerted action of their anaphylatoxins. C3
or C5 deficiency led to diminished liver regeneration, ac-
companied by transient or fatal liver failure after PHx.
Combined deficiency of both components exacerbated the
regenerative defect of the liver. The recovery of DNA syn-
thesis in regenerating hepatocytes after simultaneous recon-
stitution of C3 / C5 /  mice with C3a and C5a clearly
indicated that both anaphylatoxins are required to initiate
Figure 5. C3 deficiency and C5aRa blockade dimin-
ishes NF- B and STAT-3 activation in nuclear liver
extracts after PHx. The top depicts NF- B activation,
and the bottom shows STAT-3 activation in both
study groups as compared with their controls. Lane 1
represents NF- B in rabbit reticulocyte lysates (RRL).
WT (lanes 3 and 4) and control peptide-treated (lanes
9 and 10) mice show induction of both transcription
factors, with the strongest signal detected at 1 or 2 h
after PHx. C3 deficiency (lanes 6 and 7) and C5aRa
treatment (lanes 12 and 13) diminishes the induction
of both factors after PHx, with the most prominent
difference at 1 h in C3 /  mice (NF- B 54%- and
STAT-3 56%-less activation than in control) and 2 h
after C5aRa treatment (NF- B 60%- and STAT-3
37%-less activation than in control). The table summarizes
the reduction of activation of both transcription factors
in C3 /  and C5aRa-treated mice when compared
with control (% values). The densitometric values
from gels of two separate PHx experiments were averaged
(Materials and Methods). Lanes 2, 5, 8, and 11 represent
the baseline activation of both transcription factors in
each group without surgery.T
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hepatocyte proliferation. We demonstrated that C3 and C5
engage in the early growth response of regenerating hepa-
tocytes by mediating the activation of priming signals
(STAT-3 and NF- B), which are essential for the initiation
of the regenerative response (6). Additionally, C5aR
blockade after PHx revealed that C5aR stimulation is re-
quired for normal induction of the proinflammatory cyto-
kines IL-6 and TNF , two factors that have been identified
as crucial regulators of the regenerative capacity of hepato-
cytes. An essential role of complement in liver regeneration
is also supported by our recent paper showing that C5 / 
mice are more susceptible to toxic liver damage and display
a delayed regenerative response marked by sustained liver
necrosis (17). 
However, a clear distinction should be drawn between
these two models of liver regeneration. Acute liver toxicity
induces vigorous parenchymal regeneration but also evokes
a major inflammatory response at the site of tissue damage.
The partial hepatectomy model has now allowed us to ad-
dress the direct effect of complement on the regenerative
potential of hepatocytes without interference from a more
generalized inflammatory parenchymal insult, such as that
associated with the CCI4 toxicity model. 
Mice deficient in C3 showed severely disrupted liver re-
generation after PHx. Reconstitution of C3 /  mice with
human C3 restored their regenerative capacity, indicating
that C3 mediates a specific effect during liver regeneration.
The recovery of DNA synthesis in hepatocytes after C3a
administration to C3 /  mice suggested that C3 activation
could have an effect on regenerating hepatocytes indepen-
dent of downstream C5 activation. The partial recovery of
the regenerative phenotype of C3 / C5 /  mice upon re-
constitution with C3a or C5a further underlines the impact
of the anaphylatoxins in the regenerating liver. The com-
bined reconstitution of C3 / C5 /  animals with C3a and
C5a resulted in a significant increase of DNA synthesis in
hepatocytes and complete protection from liver damage.
These findings support the hypothesis that C3a and C5a do
not only have independent effects on liver regeneration but
they also act in concert to promote hepatocyte proliferation
after PHx. However, it has to be noted that combined C3a
and C5a reconstitution did not restore DNA synthesis to
wild type levels. This gives room to speculate on the need
for additional complement activation products other than
the anaphylatoxins. 
The in vivo administration of a specific C5aR antago-
nist provided an ideal tool for directly targeting and dis-
secting the role of C5aR stimulation and the involved mo-
lecular pathways during liver regeneration. In comparison
with C5 /  animals, C5aRa treatment displayed a more
severe impairment of liver regeneration after PHx. This
observation can be explained in a number of ways as fol-
lows. The process of liver regeneration relies on multiple
redundant pathways that ensure its control when single
components within this regulating network malfunction.
The lack of a C5a signal in C5 /  mice might be compen-
sated for by a variety of other signals during the develop-
ment of the deficient organism. In the case of short-term
C5aR blockade, a compensatory mechanism cannot be
initiated. Therefore, this blockade can unmask the actual
contribution of C5a to the regulation of liver regenera-
tion. The fact that C3 / C5 /  animals apparently cannot
compensate for their regenerative defect could suggest that
C3 and its activation products might indeed be the source
for the compensatory capability in C5 /  mice. C5aRa
treatment induced a severe regenerative defect after PHx,
which was associated with decreased levels of IL-6 and
TNF  mRNA, two cytokines that are crucial for the on-
set of regeneration (7, 34–36). This finding supported the
hypothesis that C5aR activation is required for the prim-
ing of hepatocyte regeneration. The changes in cytokine
mRNA synthesis, the decreased NF- B activation, and
the low STAT-3 activation in livers of C5aRa-treated an-
imals provide an explanation for the observed absence of
DNA replication in livers of this study group. TNF  has
been described as the main mediator of NF- B activation
in hepatocytes and nonparenchymal liver cells. In turn,
NF- B targets the IL-6 gene, leading to IL-6 synthesis
(37). Defective activation of both STAT-3 and NF- B
was also observed in C3 /  mice after PHx. Thus, C3
may either serve as an upstream mediator of C5aR activa-
tion or exert an C5a-independent effect on the early hepa-
Figure 6. Summary of the proposed mechanisms by which comple-
ment activation products modulate the priming of hepatocytes after PHx.
PHx causes among other factors the release of reactive oxygen species
(ROS) and LPS. These factors can trigger complement activation either
locally, in the portal circulation, or systemically. After complement activation
cleavage of C3 or C5 leads to the generation of the potent anaphylatoxins
C3a and C5a. Our current results support a regulatory role for these ana-
phylatoxins in liver regeneration. Their respective G-protein coupled
receptors C3aR and C5aR are activated on Kupffer cells (1) and thereby
enhance the release of TNF  and IL-6 (2). These cytokines activate NF- B
and STAT-3 in hepatocytes via the corresponding receptors, and, thus,
initiate the transcription of immediate early genes. The final transition
into G1 phase and the transcription of cell cycle genes is supported by the
activation of several transcription factors including AP-1 and CEBP/ 
(4). Alternatively, the release of IL-6 might induce C5aR activation on
hepatocytes after PHx (3). This direct effect of C5a on hepatocytes would
further promote their priming.T
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tocyte growth response by activating STAT-3 and NF-
 B. Hepatocyte DNA replication and the transcription of
a broad range of acute phase genes is known to be the re-
sult of the synergistic effect of various transcription factors
(e.g., STAT-3, NF- B, C/EBP , and AP1) (38, 39). NF-
 B activation has also been reported as a response to stim-
ulation of C5aR on mononuclear cells (40) as well as
C3aR and C5aR stimulation on HeLa cells (41). These
observations open the possibility for a direct, cytokine-
independent effect of C3a and C5a on transcription factor
activation in liver cells. In this respect, the C3 / C5 / 
animals together with the C3 /  and C5 /  animals will
help to dissect the influence of the individual anaphylatox-
ins on transcription factor activation during the early
events of liver regeneration. 
Several lines of evidence support our finding that both
anaphylatoxins contribute to the early signaling and tran-
scriptional network driving hepatocyte proliferation. It has
been reported that release of IL-6 from Kupffer cells can
be triggered by C5a in concert with LPS, thereby mediat-
ing the expression of acute-phase genes in cultured hepa-
tocytes (14). Furthermore, LPS is considered one of the
earliest priming signals for liver regeneration (11). In light
of these findings, a synergistic interaction of C5aR and
LPS-mediated pathways in nonparenchymal liver cells
seems feasible, which could modulate early responses of
hepatocytes during liver regeneration. Hepatocytes could
also serve as direct targets for C5a-dependent activation
during liver regeneration. It was recently shown that
C5aR expression can be stimulated de novo in hepato-
cytes after administration of LPS or IL-6 in rats (42).
Therefore, it is reasonable to hypothesize that IL-6 or LPS
release might affect the responsiveness of various liver cell
types to C5a stimulation, by causing an increase in C5aR
expression during liver regeneration.
In comparison to the functions of C5a, there is also evi-
dence to indicate that C3a modulates cell metabolism and
intracellular signaling. C3a was shown to modulate pros-
taglandin synthesis in cultured Kupffer cells (15) and to
change IL-6, TNF , and IL-1  production in peripheral
blood mononuclear cells (43–45). It was also reported that
C3a is capable of activating a signal transduction pathway
in endothelial cells that is distinct from C5a-dependent
mechanisms (46). These findings further support the con-
cept of a cooperative role of the two anaphylatoxins, which
might be mediated through activation of distinct signaling
pathways in target liver cells. 
Moreover, the recent identification of a second C5aR
molecule that is able to bind with high affinity not only
C5a but also C3a and C3a desArg (47) adds more complex-
ity to the interpretation of our data and provides greater
conceptual flexibility as to how these two anaphylatoxins
can interact and signal through their receptors in the liver.
The fascinating possibility that these ligands might physi-
cally share the same receptor but trigger divergent signaling
pathways, or bind to different isoforms of the same recep-
tor, and thereby activate distinct pathways in liver cells dur-
ing regeneration, cannot be excluded and warrants further
investigation. 
In conclusion, we present our working hypothesis as to
how the early mechanisms of liver regeneration that we
have discussed interact with the complement system, in-
cluding the role of the C5aR (Fig. 6). Future works are
needed to confirm the direct effect of anaphylatoxin-depen-
dent signaling on hepatocytes during liver regeneration.
We cannot exclude that complement activation products
other than C5a and C3a (such as C3b, C4a, C5adesArg,
and sublytic concentrations of C5b-9 [the membrane attack
complex]) might also play a role in hepatocyte priming. 
Liver regeneration is critical for the successful outcome
of liver resections and is especially important in the context
of living donor liver transplantations. Our results provides
new insights into the mechanisms regulating liver regenera-
tion by identifying complement components as early prim-
ing factors of hepatocytes. This finding offers a new per-
spective in the search for possible therapeutic interventions
to enhance liver regeneration.
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